03/03
Headlines

GALE

Biotech Most Volatile: Neuralstem (NYSEMKT:CUR), Aegerion Pharmaceuticals (NASDAQ:AEGR), Galena Biopharma Inc (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

Chris Lewis02 mins

Neuralstem, Inc. (NYSEMKT:CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem Inc. (NYSEMKT:CUR)’s NSI-566 stem cells in the brain experienced functional improvements. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 3.74% in last session and finished the day at $3.88. Traded volume was 2.54million shares in the…

Read More

Biotech Bearish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Galena Biopharma (NASDAQ:GALE), Insmed Incorporated (NASDAQ:INSM), CytRx Corporation (NASDAQ:CYTR)

Kristen Barton02 mins

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm currently has a $6.00 price target on the stock. Maxim Group’s target price would suggest a potential upside of 62.16% from the stock’s…

Read More

Biotech Losers: ACADIA Pharmaceuticals (NASDAQ:ACAD), Incyte Corporation (NASDAQ:INCY), Galena Biopharma (NASDAQ:GALE), Alexion Pharmaceuticals (NASDAQ:ALXN)

Colin Pettis02 mins

Board of Directors of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) adopted an updated annual incentive cash compensation program for its executive officers to be effective beginning with 2014. The description of this program is set forth in Exhibit 99.1 and is incorporated herein by reference. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock performance was -6.80% in last session and…

Read More

Biotech Most Volatile: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

Chris Lewis02 mins

MannKind Corporation (NASDAQ:MNKD) on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders…

Read More

Biotech Gainers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN)

Mark DeFrance02 mins

Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares climbed 4.96% to $3.60. The company on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same…

Read More

Biotech Active Runners: Galena Biopharma Inc. (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals Inc. (NYSEMKT:INO)

Colin Pettis02 mins

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. (NASDAQ:GALE) securities between November 6, 2013 and February 14, 2014. Galena Biopharma Inc. (NASDAQ:GALE) stock performance was -12.42% in last session and finished the…

Read More